Search Results

DiaMedica Therapeutics Inc. today announced the closing of its previously announced $11.8 million private placement to accredited investors.

IASO Biotechnology (“IASO Bio”) today announces that the investigational new drug (IND) application for RD118, an independently developed, fully human GPRC5D-targeting chimeric antigen receptor T-cell (CAR-T) therapy, has been approved by the National Medical Products Administration (NMPA) for treatment of relapsed/refractory multiple myeloma (RRMM).

Anova Enterprises, Inc. has collaborated with University of California at San Francisco, University of California at San Diego, the University of Southern California and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.

Denovo Biopharma LLC (Denovo) today announced that the California Institute for Regenerative Medicine (CIRM) has awarded a $11.8M grant for further development of DB107, Denovo’s DGM7™ biomarker–guided late–stage gene therapy, for high–grade glioma (HGG) including glioblastoma (GBM), a malignant brain cancer.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors.

Zenas BioPharma closed on a Series B financing round worth $118 million, which it will use to advance its autoimmune candidate obexelimab into a global Phase III trial later this year.

Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, announced proceeds of $118 million in connection with the issuance of Series B preferred shares.

Mineralys Therapeutics, a clinical-stage biopharmaceutical company focused on developing a best-in-class, novel therapy for high blood pressure, closed a $118 million Series B investment round.

Amplifica Holdings Group, Inc., a privately-held, clinical-stage biopharmaceutical company announced it successfully closed an $11.8 million Series A Preferred Stock financing.